Figures & data
Figure 1 Percentage changes in lumbar BMD (A) and total hip BMD (B) before, and at 6–8, 12, 18, and 24 months after denosumab therapy.
Abbreviations: BMD, bone mineral density; M, months.
![Figure 1 Percentage changes in lumbar BMD (A) and total hip BMD (B) before, and at 6–8, 12, 18, and 24 months after denosumab therapy.](/cms/asset/1ae02b1b-c1e8-4cbd-a2ca-4c91de736fe2/dtcr_a_162574_f0001_b.jpg)
Figure 2 Percentage changes in BAP (A), urinary NTX (B), serum TRACP-5b (C), and active form of vitamin D or 1,25(OH)2D3 (D) before, and at 1, 4, 8, 12, 18, and 24 months after denosumab therapy.
Abbreviations: BAP, bone alkaline phosphatase; NTX, cross-linked N-terminal telopeptides of type I collagen; TRACP-5, tartrate-resistant acid phosphatase 5b; M, months.
![Figure 2 Percentage changes in BAP (A), urinary NTX (B), serum TRACP-5b (C), and active form of vitamin D or 1,25(OH)2D3 (D) before, and at 1, 4, 8, 12, 18, and 24 months after denosumab therapy.](/cms/asset/713c8047-039c-40cb-b416-0c7fe81054a8/dtcr_a_162574_f0002_b.jpg)
Table 1 Patient laboratory data
Table 2 Patient bone mineral density
Table 3 Patient laboratory data (bone metabolism markers)